Moffitt | Strategic Alliance Partners

May 04, 2021

Michael Shafique, MD, discusses treatment considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.

April 30, 2021

Andreas Saltos, MD, discusses the importance of broad molecular testing in non–small cell lung cancer.

April 14, 2021

April 09, 2021

Hye Sook Chon, MD, teases out some of the differences between the data with PARP inhibitors in the frontline maintenance setting and shed light on ongoing research with combinations that could broaden their utility in patients with advanced ovarian cancer.

March 31, 2021

HEPZATO KIT has demonstrated statistically significant benefit compared to best alternative care in patients with liver-dominant metastatic ocular melanoma, according to preliminary results from the phase 3 FOCUS trial.

March 30, 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses future directions with antibody-drug conjugates in the treatment of patients with ovarian cancer.